MS-282A(MS-282A) - 药物靶点：Phosphotransferases_专利_临床

概要

基本信息

药物类型

未知

别名

靶点

Phosphotransferases

作用机制

磷酸转移酶抑制剂

治疗领域

免疫系统疾病心血管疾病呼吸系统疾病

在研适应症-

非在研适应症

哮喘心肌缺血

原研机构

Kyowa Kirin Co., Ltd.

在研机构-

非在研机构

Kyowa Kirin Co., Ltd.

最高研发阶段终止临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 MS-282A 相关的临床结果

登录后查看更多信息

100 项与 MS-282A 相关的转化医学

登录后查看更多信息

100 项与 MS-282A 相关的专利（医药）

登录后查看更多信息

1

项与 MS-282A 相关的文献（医药）

1994-01-01·The Journal of Antibiotics4区 · 医学

MS-282a and MS-282b, new inhibitors of calmodulin-activated myosin light chain kinase from Streptomyces tauricus ATCC 27470.

4区 · 医学

Article

作者: Mayumi Yoshida ; Katsunori Kita ; Yutaka Saitoh ; Satoshi Nakanishi ; Youichi Uosaki ; Isao Kawamoto ; Akira Mihara ; Yuzuru Matsuda

MS-282a and MS-282b were isolated from the culture broth of Streptomyces tauricus ATCC 27470 as inhibitors of smooth muscle myosin light chain kinase (MLCK). MS-282a and MS-282b inhibited the activity of chicken gizzard MLCK with IC50 values of 3.8 microM and 5.2 microM, respectively. Cyclic AMP-dependent protein kinase, cyclic GMP-dependent protein kinase and protein kinase C were not inhibited by 150 microM MS-282a at all. It is likely that MS-282a blocks MLCK activity by antagonizing calmodulin since 1) the compound inhibited calmodulin-dependent but not calmodulin-independent activity of MLCK; 2) the inhibition of MLCK was antagonized by increasing concentrations of calmodulin, and 3) the compound inhibited calmodulin-dependent cyclic nucleotide phosphodiesterase.

100 项与 MS-282A 相关的药物交易

登录后查看更多信息